DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 1

Completed

Conditions: Merkel Cell Carcinoma

Interventions: Drug: MLN0128

First Posted Date: 2015-08-04

Last Posted Date: 2020-12-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT02514824

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)

Completed

Conditions: Lung Cancer

Interventions: Other: VATS-associated best practices

First Posted Date: 2015-07-20

Last Posted Date: 2020-01-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 173

Registration Number: NCT02502695

Locations: 🇺🇸
Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
WellStar Medical Group, Austell, Georgia, United States

and more 3 locations

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: LY2452473

First Posted Date: 2015-07-16

Last Posted Date: 2021-09-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 114

Registration Number: NCT02499497

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center (Referring site only), Boston, Massachusetts, United States

and more 1 locations

The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma And/or DCIS in Patients Diagnosed with Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy

Not Applicable

Active, not recruiting

Conditions: Flat Epithelia Atypia
Intraductal Papilloma Without Atypia

Interventions: Other: Pathologic evaluation of excised tissue

First Posted Date: 2015-07-03

Last Posted Date: 2024-11-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 246

Registration Number: NCT02489617

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Sibley Memorial Hospital, District of Columbia, District of Columbia, United States
🇺🇸
Georgetown University, Washington, D.C., District of Columbia, United States

and more 15 locations

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: Ponatinib

First Posted Date: 2015-06-23

Last Posted Date: 2018-07-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 17

Registration Number: NCT02478164

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Phase 1

Active, not recruiting

Conditions: Head and Neck Cancer Metastatic
Recurrent Head and Neck Carcinoma
Head or Neck Cancer

Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT)
Drug: Cisplatin
Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2015-06-17

Last Posted Date: 2024-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT02474368

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Not Applicable

Completed

Conditions: Adenocarcinoma of the Prostate Stage I
Adenocarcinoma of the Prostate Stage II
Prostate Cancer
Adenocarcinoma of the Prostate Stage III

Interventions: Device: Magnetic Resonance Imaging

First Posted Date: 2015-06-12

Last Posted Date: 2019-12-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT02470910

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors

Not Applicable

Terminated

Conditions: Fatigue in Cancer Survivors

Interventions: Other: Placebo

First Posted Date: 2015-05-25

Last Posted Date: 2018-12-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02452710

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer Stage IV
Metastatic Invasive Breast Cancer
Unresectable Locally Advanced Invasive Breast Cancer

Interventions: Drug: Palbociclib
Drug: Bazedoxifene

First Posted Date: 2015-05-19

Last Posted Date: 2022-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT02448771

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone
Procedure: Stem Cell Mobilization
Procedure: Autologous Stem Cell Transplant

First Posted Date: 2015-05-12

Last Posted Date: 2024-10-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT02441686

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Virginia Piper Cancer Institute, Coon Rapids, Minnesota, United States
🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy